Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
RegulatoryNegative
AI Analysis
Summary
Newron Pharmaceuticals disclosed five deaths in its late-stage schizophrenia program—four among drug recipients and one in the placebo group—prompting the FDA to maintain a hold on the program. The hold was initially triggered by a single patient death earlier in 2026.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA hold maintained following four deaths among drug recipients and one death among placebo recipients in late-stage schizophrenia program
Importance:9/10
Sentiment:
-0.95
FDA holdsafety concerndeathsschizophreniaclinical trial
Related Companies
Read the original article
Published by BioSpace on October 8, 2026 1:51 PM